CoreValve Cleared For Lower-Risk TAVR In Europe Clinicians eye a similar expansion for TAVR in the U.S.

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$450 Annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

CoreValve Cleared For Lower-Risk TAVR In Europe Clinicians eye a similar expansion for TAVR in the U.S.

Posted: 08/02/2016
Author:
Nicole Lou Reporter, MedPage Today/CRTonline.org
Adult Congenital Heart Disease Valve & Structural

The CoreValve Evolut R System has been cleared by European regulators for treating intermediate-risk patients, making it the first transcatheter aortic valve replacement (TAVR, also known as TAVI) device to win an expanded indication for this population.

Most Viewed Pages

First-in-Human Percutaneous Removal of Left Atrial Appendage Occlusion Devices With a Novel Retrieval System

Technology viewpoint: Evolution in PCI: The next major advance in implant technology to restore vessel function

Watchful Waiting Strategy in Extensive Iatrogenic Aortic Dissection Complicating Percutaneous Coronary Intervention

Episode 14 | Short DAPT the Ultimate DAPT study and the Guidelines

Preventative PCI with Optimal Medical Therapy Reduces Long-Term MACE in Patients with Non-Flow-Limiting Vulnerable Plaques: PREVENT Trial

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

CoreValve Cleared For Lower-Risk TAVR In Europe Clinicians eye a similar expansion for TAVR in the U.S.

Most Viewed Pages

Explore the Site

Stay Connected